Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
50,702,920
-
Share change
-
+251,682
-
Total reported value
-
$4,327,234,538
-
Put/Call ratio
-
35%
-
Price per share
-
$85.35
-
Number of holders
-
295
-
Value change
-
+$21,150,132
-
Number of buys
-
141
-
Number of sells
-
156
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q1 2024
As of 31 Mar 2024,
HAEMONETICS CORP - Common Stock (HAE) was held by
295 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,702,920 shares.
The largest 10 holders included
Capital Research Global Investors, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, NEUBERGER BERMAN GROUP LLC, STATE STREET CORP, FRANKLIN RESOURCES INC, ROYCE & ASSOCIATES LP, T. Rowe Price Investment Management, Inc., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
296
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.